Coeptis Therapeutics Holdings Inc., through its subsidiary SNAP Biosciences, Inc., has entered into a licensing agreement with Monarch Therapeutics Inc. to enhance the development of its SNAP-CAR NK cell therapy platform in oncology. This partnership grants SNAP Biosciences access to Monarch's innovative small-molecule adaptor technology, broadening the functionality of the Snap-Car universal CAR-based receptor platform. The collaboration aims to advance the precision, flexibility, and scalability of NK therapies, targeting multiple tumor antigens and addressing challenges in oncology treatment. Monarch Therapeutics will receive upfront licensing payments, potential development milestone payments, and royalties on net sales as part of the agreement. This initiative is expected to transform outcomes for patients with difficult-to-treat cancers.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.